Protagonist Therapeutics, Inc. (PTGX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
7707 Gateway Boulevard
Newark, CA 94560
United States of America (the)
Phone
510 474 0170
Sector
Healthcare
Industry
Biotechnology
Employees
132
First IPO Date
August 11, 2016
| Name | Title | Pay | Year Born |
| Dinesh V. Patel | Chief Executive Officer, President, Secretary & Director | 1.41M | 1957 |
| Asif Ali | Executive Vice President & Chief Financial Officer | 826,242 | 1974 |
| Arturo Molina FACP | Chief Medical Officer | 949,992 | 1959 |
| Carena Spivey | Executive VP & Chief Human Resources Officer | 0 | N/A |
| Ashok Bhandari | EVP & Chief Discovery Officer | 0 | 1964 |
| Newman Yeilding | Executive Vice President, Chief Scientific Officer | 0 | N/A |
| Carter J. King | Executive Vice President of Business Development | 0 | 1971 |
| Matthew Gosling | Executive Vice President and Chief Legal & Business Officer | 0 | 1971 |
| Venkat Thalladi | EVP & Chief Technical Officer | 0 | N/A |
| Abha Bommireddi | Executive Vice President & Chief of Staff | 0 | N/A |
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.